ThinkGenetic is set to release a version of its online interactive tool to help in the diagnosis of Fabry disease as part of upcoming pilot initiatives by Takeda Pharmaceutical. The initial pilot programs, to be released this year, will also include versions of the diagnostic tool, called…
The U.S. Food and Drug Administration (FDA) has extended the review date by three months — to spring 2021 — for a biologics license application (BLA) seeking accelerated approval of PRX-102 (pegunigalsidase alfa) to treat adults with Fabry disease. Protalix BioTherapeutics and Chiesi Global Rare Diseases, who are…
The European Commission has granted orphan drug designation to Avrobio’s investigational gene therapy AVR-RD-01 for the treatment of Fabry disease. The decision, based on a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency, will provide regulatory and financial incentives for…
Get regular updates to your inbox.